Longeveron Completes Investigator Meeting in Pediatric Heart Trial, Shares Rise

Regenerative medicine company, Longeveron (Nasdaq: LGVN) topped the PRISM MarketView Global Health index on Wednesday after the company’s share price soared nearly 12% in morning trading. Longerveron announced this week the successful completion of an investigator meeting for ELPIS II, the company’s ongoing Phase 2b clinical trial evaluating Lomecel-B™ as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric congenital heart birth defect.

“We believe the data generated to date in HLHS support potential for Lomecel-B™ as a regenerative medical therapy to help these infants,” said Nataliya Agafonova, MD, Chief Medical Officer of Longeveron. “In the ELPIS I Phase 1 clinical trial, participating infants experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to an approximate 20% mortality rate observed from historical control data. ELPIS II is designed to further our understanding of Lomecel-B’s™ safety and efficacy in this patient population. With the collaboration of our outstanding investigative sites, we remain on track to complete enrollment of the clinical trial by the end of this year.”

ELPIS II is on track to complete enrollment at multiple nationally recognized children’s treatment centers by the end of 2024.

HLHS is a congenital birth defect in which the left ventricle is either underdeveloped or missing. Infants born with this condition must undergo a complex, three-stage heart reconstruction surgery during the first 5 years of their lives. There is an important unmet medical need to improve right ventricular function in these patients.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Share This Article


About the Author

Longeveron Completes Investigator Meeting in Pediatric Heart Trial, Shares Rise

Catie Corcoran

Biotech Editor